Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v17-EN Version v4-FR
Language English French
Date Updated 2023-07-11 2023-03-31
Drug Identification Number 02182955 02182955
Brand name METHOTREXATE INJECTION USP METHOTREXATE INJECTION USP
Common or Proper name METHOTREXATE INJECTION USP METHOTREXATE INJECTION USP
Company Name PFIZER CANADA ULC PFIZER CANADA ULC
Ingredients METHOTREXATE METHOTREXATE
Strength(s) 25MG 25MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRATHECAL INTRAMUSCULAR INTRA-ARTERIAL INTRACEREBROVENTRICULAR INTRACEREBROVENTRICULAR INTRAVENOUS INTRATHECAL INTRAMUSCULAR INTRA-ARTERIAL INTRAVENOUS INTRATHECAL INTRAMUSCULAR INTRA-ARTERIAL INTRACEREBROVENTRICULAR INTRACEREBROVENTRICULAR INTRAVENOUS INTRATHECAL INTRAMUSCULAR INTRA-ARTERIAL
Packaging size 1 x 2mL vial 1 x 2mL vial
ATC code L01BA L01BA
ATC description ANTIMETABOLITES ANTIMETABOLITES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2023-05-05
Actual start date 2023-06-19
Estimated end date 2023-07-31
Actual end date 2023-07-10
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments 5 vial pack presentation remains available.
Health Canada comments